Boehringer Ingelheim embraces dual-pricing tactic with launch of unbranded Humira biosimilar
4th October 2023 Uncategorised 0 Boehringer Ingelheim embraces dual-pricing tactic with launch of unbranded Humira biosimilar
fkansteiner
Wed, 10/04/2023 – 10:34
More: Boehringer Ingelheim embraces dual-pricing tactic with launch of unbranded Humira biosimilar
Source: fierce
